Drugs / Verubecestat
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02910739 | Oct 2016 → Apr 2017 | Alzheimer disease, amnestic disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01537757 | Mar → May 2012 | Alzheimer disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01496170 | Dec 2011 → Jun 2012 | Alzheimer disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT01739348 | Nov 2012 → Apr 2017 | Alzheimer disease | Merck Sharp & Dohme LLC | Terminated | Missed primary |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT01953601 | Nov 2013 → Apr 2018 | Alzheimer disease, amnestic disorder | Merck Sharp & Dohme LLC | Terminated | Missed primary |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2018-02-13 | Merck Sharp & Dohme LLC | Results Merck Announces Discontinuation of APECS Study Evaluating Verubecestat (MK-8931) for the Treatment of People with Prodromal Alzheimer’s Disease merck.com ↗ |
| 2017-02-14 | Merck Sharp & Dohme LLC | Results Merck Announces EPOCH Study of Verubecestat for the Treatment of People with Mild to Moderate Alzheimer’s Disease to Stop for Lack of Efficacy merck.com ↗ |
| 2016-11-02 | Merck Sharp & Dohme LLC | Results Merck Scientists Publish New Research Detailing the Early Development of Verubecestat, an Investigational BACE1 Inhibitor in Science Translational Medicine merck.com ↗
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the publication of research conducted by Merck scientists on the discovery and development of verubecestat, an investigational small molecule inhibitor of the enzyme beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), for the potential treatment of Alzheimer’s disease (AD). |
| 2013-12-10 | Merck Sharp & Dohme LLC | Results Merck Advances Development Program for Investigational Alzheimer’s Disease Therapy, MK-8931 merck.com ↗
The Data Monitoring Committee (DMC) for the Phase II/III “EPOCH” study in patients with mild to moderate Alzheimer’s disease recently completed its planned interim safety analysis and recommended that the trial continue to recruit patients, with no changes to the protocol. |
| 2013-07-14 | Merck Sharp & Dohme LLC | Results Merck Presents Findings from Phase 1b Study of Investigational BACE Inhibitor, MK-8931, in Patients with Alzheimer’s Disease merck.com ↗
The data were presented during an oral session at the Alzheimer’s Association International Conference (AAIC) in Boston, July 13-18 (Abstract O1-06-05). |
| 2012-04-27 | Merck Sharp & Dohme LLC | Results Merck Presents Results of a Phase I Clinical Trial Evaluating Investigational BACE inhibitor MK-8931 at American Academy of Neurology merck.com ↗
Merck, known as MSD outside the United States and Canada, today presented Phase I data evaluating the safety and tolerability of its novel, oral β-amyloid precursor protein site cleaving enzyme (BACE) inhibitor, MK-8931, being investigated as a potential treatment for Alzheimer’s disease. |
All press releases naming this drug 8 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | verubecestat | “The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients.” PMID 27807285 ↗ Nov 2016 |
| Known as | MK-8931 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01537757 ↗ |
| Known as | SCH 900931 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301601 ↗ |
| Known as | VERUBECESTAT (MK-8931) | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301601 ↗ |
| Action | Inhibit | “verubecestat (MK-8931) is a potent, selective, structurally unique BACE1 inhibitor” PMID 27807285 ↗ Nov 2016 |
| Modality | Small molecule | — CHEMBL3301601 ↗ |
| Route | Oral | “MK-8931, capsules, at a dose of 12 or 40 mg, orally, once per day for 7 days” NCT01496170 ↗ |
| Target | BACE1 | “The BACE1 inhibitor verubecestat” PMID 27807285 ↗ Nov 2016 |